Welcome to our dedicated page for Cellectis news (Ticker: CLLS), a resource for investors and traders seeking the latest updates and insights on Cellectis stock.
Cellectis S.A. develops gene-edited cell and gene therapies as a clinical-stage biotechnology company. Its recurring news centers on allogeneic CAR T immunotherapies in oncology, including off-the-shelf, gene-edited CAR T-cell product candidates, and on broader gene therapy research using its gene-editing platform and in-house manufacturing capabilities.
Company updates commonly cover clinical and partner-program developments for candidates such as lasme-cel, eti-cel and cema-cel; TALE-based and epigenetic editing research; financial results and business updates; collaborations and license arrangements; and monthly disclosures of share capital and voting rights for its Euronext Growth listing alongside its Nasdaq-listed ADS trading under CLLS.
Cytovia Therapeutics and Cellectis have formed a strategic collaboration to develop TALEN® gene-edited iPSC NK and CAR-NK cells. This partnership could yield up to $760 million in milestones for Cellectis. Cellectis will get single-digit royalties on sales of partnered products. Cytovia is responsible for the clinical development of these therapies, aiming for trials by 2022. The collaboration is anticipated to enhance NK cell therapies' efficacy for various cancers, capitalizing on Cellectis' gene-editing expertise to improve safety and effectiveness.
Cellectis, a clinical-stage biopharmaceutical company, is pioneering allogeneic CAR-T immunotherapies using its TALEN® gene editing technology. As of January 31, 2021, the company has a total of 43,029,305 shares and 49,093,894 voting rights. Cellectis focuses on developing UCART product candidates to treat unmet medical needs in various cancers including acute myeloid leukemia and multiple myeloma. The company operates in Paris, New York, and Raleigh, and is listed on both Nasdaq (CLLS) and Euronext Growth (ALCLS).
Cellectis announced a registered direct offering through its subsidiary Calyxt, securing $15 million by selling 3,750,000 shares at $4.00 each. Cellectis will purchase 1,250,000 shares, raising its ownership stake in Calyxt to 64.7%. The offering, set to close around October 20, 2020, will fund general corporate purposes, including advancing product development and TALEN® technology. H.C. Wainwright & Co. acts as the exclusive placement agent. The shares are offered under an effective SEC registration statement.
Cellectis announced updates on its share capital and voting rights as of September 30, 2020. The total number of shares in the capital reached 42,486,133, while the total voting rights amounted to 47,940,528. Specializing in CAR-T immunotherapies, Cellectis focuses on innovative gene editing technologies to treat various cancers, including acute myeloid leukemia and multiple myeloma. The company’s mission is to provide effective UCART product candidates to address unmet medical needs in oncology.
Cellectis announced its commitment to advancing CAR-T immunotherapies, focusing on off-the-shelf gene-edited T-cells for cancer treatment. As of August 31, 2020, the company has 42,486,133 shares outstanding and 47,940,778 voting rights. Their innovative approach leverages TALEN® technology to target a range of cancers including AML, B-ALL, and MM. Headquartered in Paris, Cellectis is publicly traded on both Nasdaq (CLLS) and Euronext Growth (ALCLS). The company aims to meet urgent medical needs in oncology, leveraging over 20 years of gene editing expertise.
Cellectis (Nasdaq: CLLS), a clinical-stage biopharmaceutical company, announced participation in several investor conferences to showcase its advancements in gene-edited CAR T-cell therapies. Notable events include presentations at the Citi Annual BioPharma Conference on September 9, 2020, and the Wells Fargo Healthcare Conference on September 10, 2020. Cellectis focuses on developing innovative treatments for various cancers using proprietary technologies like TALEN® and PulseAgile.
The company's goal is to provide life-saving UCART therapies for unmet cancer treatment needs.